Medical network - on September 4, in the first half of the world economic growth, international trade as a whole from the low recovery of environment, western medicine products of foreign trade in our country restorative growth, imports and exports reached $33.688 billion, up 17.06% from a year earlier, to return to double-digit growth in the first two years. Due to the products of foreign trade growth rate significantly higher than that of traditional Chinese medicine and western medicine medical device products of foreign trade growth rate (5.54% and 4.19%, respectively), import and export of western medicine proportion of foreign trade in our country for the first time since 2010 to pick up to more than 60%.
Similar to the overall situation of China's foreign trade, the export and import trade of western medicine products has gained momentum. Among them, the value of exports was 16.87 billion us dollars, up 7.55% year on year. Imports were $16.818 billion, up 28.46 percent year on year. The import and export trade was more balanced, with a trade surplus of only us $5157 million, down 98 per cent year-on-year.
export
The increase in prices continues
From January to June 2017, China's export of western pharmaceutical products was 488.07 million tons, a year-on-year increase of 9.7 percent, and the number of exports hit a record high in the first half of the year. At the same time, however, the average export price has fallen by 1.96 per cent year-on-year, continuing the downturn in recent years.
Monthly figures for the first half of the year showed a slight decline in exports in February from a year earlier, while the rest of the month showed varying degrees of growth. In terms of the quantity price, the amount of the first and February was deviated from the obvious, then gradually steadier, the export volume growth momentum slowed, and the average export price changed from the fall to the same year.
On the macro level, the export situation of China's western medicine products has not been separated from the channel that has been falling; But the trend is now ending with monthly data analysis. This is related to the recovery of international economic growth and the recovery of the purchasing power of the international market.
The growth of raw materials and biochemical drugs is obvious
In the first half of 2017, the export pattern of three categories of western medicine products in China remained stable. The export of raw materials is up to 82.88%, which is up; The proportion of the export of western medicine and biochemical medicine decreased slightly to 9.16% and 7.96% respectively.
Specifically, the export amount of China's raw material medicine reached $13.981 billion in the first half of the year, an increase of 8.18% year on year, and the increase was relatively obvious. The number of exports reached 450.22 million tons, an increase of 9.89 percent year on year, which led to the export growth of raw materials in the case of a 1.56 percent drop in the average export price. Large varieties of active pharmaceutical ingredients, amino acids, vitamins, aminoglycoside appeared a double-digit year-on-year growth, antipyretic analgesic, cephalosporins, hormones, such as export growth is more prominent, sulfa, clindamycin, chloramphenicol, respectively, such as a significant export growth.
In the first half of the year, the export volume of western medicine preparations was $15.45 billion, 0.98 percent year-on-year, with the number of exports increased by a small 3.73 percent, while the average export price dropped by 2.65 percent. Among them, the growth rate of hormone and cephalosporin was in double digits, which was excellent.
The number of bio-drug exports rose 10.66 per cent from a year earlier, and even with a 1.39 per cent drop in exports, the export volume was 9.12 per cent year-on-year, with exports reaching $13.44 billion. Both heparin and peptone derivatives have relatively fast export growth.
America returns to the top
In the first half of 2017, our products export to western medicine market is still focused on the two great continents, total exports accounted for 72%, but export growth were 6.18% and 5.63% respectively, lower than western medicine overall export growth. Exports to North America and Latin America grew at a faster rate of 13.84 per cent and 11.16 per cent respectively, but the proportion of exports remained small. Look from the relationship between quantity and price, the price of exports to Latin America and Oceania deviate from the obvious, for both western medicine products export Numbers are growing by more than 22%, but exports average fell more than 10%; The price of exports to Asia and North America is relatively stable, with a slight decline of only about 1%. Exports to Africa are rising in price.
China's western medicine products exported to 200 countries and regions in the first half of the year, which accounted for 57.5% of the exports to the top ten countries.
In the first half of this year, China's exports of western pharmaceutical products reached us $2.24 billion, up 13.77 per cent year on year. Among them, the API exports accounted for 82%, API export categories, amino acids, hormones, antipyretic analgesic category, vitamins, central nervous system, such as exports are achieved strong growth, but the clindamycin, tetracycline, penicillin exports appeared a certain degree of decline. In western medicine preparations on the export of China's enterprises have not been able to continue rapid growth last year, exports are only 3.51% year-on-year growth, exports jumped 55% average price is remarkable, however, shows China's exports to the United States of the western medicine preparations of high value-added products.
India from western medicine in our country export destination countries fell off list, into second place by a tiny margin, in the first half of our country on the western medicine products exports was $2.228 billion, up 6.94% from a year earlier, the export quantity slightly less than 1% of the cases, export average price rose nearly 8%. Among them, China's exports to India apis to occupy 94% of the total amount of China's exports to the western medicine products, cephalosporins, vitamin, antipyretic analgesic category, aminoglycoside, cardiovascular system, such as exports are achieved double-digit year-on-year growth, and amino acids, hormones, such as large ring lactone class exports fell. In particular, since last year, India has initiated an anti-dumping investigation against my homemade amoxicillin and ofloxacin, leading to a decline in exports of related goods in India in the first half of the year.
At the top of the western medicine export destination countries list 3 ~ 7 was followed by Japan, South Korea, Germany, the Netherlands, Brazil, and ranked ninth in Thailand, increase to some extent to the export in our country, especially for the German western medicine products exports year-on-year growth rate as high as 18%; Italy and 10th Spain, which were in eighth place, saw some negative growth, particularly as Spain's exports were hit by a local strike, which fell by 14%.
Private enterprises are vigorous and vigorous
In the first half of the year, the number of enterprises that operate the export of western pharmaceutical products continued to increase, to 1,0074, an increase of 594 over the same period last year. Private enterprises are still the main force of China's western pharmaceutical exports, with a total of 8,041 export enterprises and 58 percent of the export volume, while the export volume also achieved 6.46% year-on-year growth rate. The three capital enterprises have performed well, with a total of 29 percent of western pharmaceutical products exported to China, with a year-on-year increase of 12 percent. The export vitality of state-owned enterprises continued to decline. In the first half of this year, the export volume of western pharmaceutical products only increased by 2.9 percent.
In thousands of companies, multinational giant astrazeneca western medicine products export explosive growth, growth is as high as 715%, and took the western medicine export enterprises in our country first name list, reason is quite likely the its production base in domestic production and sales at home and abroad to benefit from the year before. The export volume of enterprises such as huayi pharmaceutical and geno pharmaceutical also achieved high growth, with the former of the former and the balanced growth of the preparation, the latter mainly relying on the export growth of raw materials.
import
The price has increased to promote growth
From January to June 2017, China imported 90.68 million tons of western pharmaceutical products, a year-on-year increase of 16.9%, and the import volume reversed last year's decline. Average import prices continued to rise, up 9.88 percent year on year.
From the monthly data, the import amount of western medicine products has increased by more than double digits, with the year-on-year increase of 40% in January and may. Imports have also increased in varying degrees, with import prices falling only in February and rising in the rest of the month.
Imports surged in three categories
In the first half of 2017, the three categories of China's western medicine products imported rapidly. The year-on-year increase in the import of biochemical drugs was up to 32.9%, which resulted from the increase in China's import demand for immune products, anti-serum, insulin and human vaccines. Western medicine preparation import growth also is as high as 32.49%, hormones, vitamins, and most of the species, such as penicillin, anti-infective drug imports surge, the western medicine products in our country in western medicine preparations imports the proportion of imports of more than 50% for the first time; The import growth of raw materials was the lowest, but it was also 17.84%, and the increase in the import of vitamins and cardiovascular systems was obvious.
European sources account for nearly 70%
Europe has been the main source of imported western medicine products. In the first half of the year, the amount of western pharmaceutical products imported from Europe reached us $11.489 billion, up 27.26% year on year, which accounted for 68% of the total imports of western medicine products in China. Imports from Asia and North America also increased by 25 per cent and 58 per cent respectively, while imports from Latin America and Africa fell.
The top 10 of China's western medicine products imported from the countries of origin, excluding the United States and Japan, are all eu countries, which are sufficient to illustrate the strong position of Europe in the western medicine import market in China. In the first half of the year, the import volume of China's top ten countries increased by 5% to 59%, and the total amount of imports accounted for nearly 80%. Among them, Germany was the top of the list, accounting for 1/5 of the total import volume of western pharmaceutical products from China, far ahead of other countries. The United States came second, with China's imports from its top 10 in the top 10, up 59.39 percent from a year earlier.
The three capital enterprises are still the main force
In the first half of the year, the number of enterprises that operate the import of western pharmaceutical products continued to increase, reaching 5,943, an increase of 289 over the same period last year. Among them, the top three enterprises with the largest number of enterprises are still imported major forces, and 2,847 enterprises have contributed 71% of the import of western medicine products, and the increase in the value of imports has reached 30.39% year-on-year. The import growth of private enterprises was slightly higher, with 28.28% increase their import proportion to 16%. The share of imports from state-owned enterprises has fallen to 13%.
Looking forward to
Environment recovery, risk still cannot be ignored
In the first half of 2017, the global economic situation continued to improve, presenting the first "simultaneous recovery" in seven years. In advanced economies, the us, the eurozone and Japan have generally recovered. In emerging economies, China and India continue to lead growth, and Russia and Brazil are emerging from recession. The international monetary fund and the world bank have raised global growth forecasts. International trade and investment continue to rebound, the WTO released by the world trade climate index for the highest level since May 2011, the international investment is also showing a sustained growth momentum, indicates the further recovery of world economy.
Under the environment influence, western medicine products at home and abroad continue to steady demand growth, combined with the Chinese government this year to continue the burden for the enterprise, accelerating the development of new formats, adjusting the trade structure, work harder to build favorable environment, to provide multiple power to promote trade growth, western medicine products in our country present ShuangWang situation of import and export trade. In the second half of the year, the import volume of Chinese western medicine products will continue the growth momentum of the first half of the year, maintaining the double-digit annual growth rate.
But there are still many uncertainties about growth in the second half of the year. One is that inflation in major economies, such as the us and the euro zone, is still facing challenges in global economic growth. Second, the United States has threatened to launch a "301 investigation" against China, and unilateral trade protectionism is on the rise, adding new uncertainties to the international trade situation. Third, the increase in the probability of geopolitical and military conflicts, the nuclear issue and the Syrian armed conflict will have negative effects on the international economy and trade. Four drug regulatory situation at home and abroad is becoming more and more strict, especially domestic agency GMP flight check increasingly frequent, generics consistency evaluation into the deepening the execution phase, gradually tightening environmental policy, enterprise survival pressure continues to increase, Five is to focus on the international market, seek increased Numbers of the domestic enterprise engaged in the import and export of western medicine, this will inevitably lead to more competitive, western medicine products export average falling are also associated with this. (the writer is from the China health insurance chamber)
|
